Personalis (NASDAQ:PSNL) Price Target Raised to $9.00

Personalis (NASDAQ:PSNL) had its price objective upped by investment analysts at Lake Street Capital from $7.00 to $9.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s price target would suggest a potential upside of 68.22% from the company’s previous close.

A number of other brokerages have also recently commented on PSNL. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Personalis in a research note on Wednesday. Needham & Company LLC restated a “buy” rating and set a $7.25 target price on shares of Personalis in a research report on Wednesday.

Personalis Price Performance

Shares of PSNL stock traded down $0.63 on Wednesday, reaching $5.35. 874,950 shares of the stock were exchanged, compared to its average volume of 929,288. The stock has a 50 day moving average price of $4.68 and a 200 day moving average price of $4.31. The stock has a market cap of $377.97 million, a PE ratio of -3.18 and a beta of 1.75. Personalis has a one year low of $1.12 and a one year high of $7.20.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $25.71 million for the quarter, compared to analyst estimates of $20.67 million. During the same quarter in the prior year, the firm earned ($0.51) EPS. On average, research analysts expect that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of Personalis

A number of institutional investors have recently modified their holdings of the company. nVerses Capital LLC bought a new stake in Personalis in the 3rd quarter valued at approximately $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after acquiring an additional 4,504 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in shares of Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after buying an additional 17,082 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Personalis in the 3rd quarter valued at about $210,000. Finally, Barclays PLC raised its holdings in shares of Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after purchasing an additional 20,444 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.